Condition: Presumed Ocular Histoplasmosis · Sponsor: Cincinnati Eye Institute, Southwest Ohio
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)
This description comes directly from the study's public registry record.
Kelye Conrad, Clinical Research Manager · 1+513-569-3688 · kconrad@cvphealth.com
Always discuss trial participation with your own doctor first.
| Cincinnati Eye Institute | Cincinnati, Ohio, United States | Recruiting |
| CVP Physicians Dayton | Dayton, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07695298